Join our daily newsletter At The Bell to receive exclusive market insights
- THC Global (THC) will have its first Canndeo branded medicinal cannabis products on the Australian market next month
- CEO Ken Charteris says Australians will now have access to homegrown and high-quality medicinal cannabis
- THC’s medical and clinical affairs team, CanndeoCare, will help support and educate healthcare professionals on prescribing medicinal cannabis to patients
- The company has also entered a product distribution agreement with ACA Müller, a German pharmaceuticals importer
- ACA will distribute THC’s medicines and oils across Europe, with the first order expected to be placed by September this year
- THC is up 1.61 per cent on the market this afternoon, trading for 31.5¢ per share
THC Global (THC) will have its first Canndeo branded cannabis medicines on the Australian market in May.
The company’s medicines use Australian cannabis plant material and are manufactured at its Southport pharmaceuticals GMP facility.
CEO Ken Charteris says Australians will now have access to homegrown and high-quality medicinal cannabis.
“These medicines will be more affordable and accessible than current products available in Australia, ensuring that more Australian patients in need of these medicines can access them safely through legal access pathways and with the right medical support and supervision,” he said.
THC’s medical and clinical affairs team, CanndeoCare, will help support and educate doctors and healthcare professionals in prescribing medicinal cannabis to patients.
The medicines will be directly supplied to pharmacies, clinics and hospitals.
European distribution agreement
THC has also announced it has entered into a product distribution agreement with ACA Müller, a German pharmaceuticals importer.
Under this agreement, ACA will distribute the company’s Canndeo and EU GMP medicines and oils across Europe, with the first order expected to be placed by September 2020.
ACA is a subsidiary of Franchise Cannabis Corp who hold the first cannabis licence granted in Germany.
“This is a strategic milestone for the company to date which will allow us to diversify our product base into high-quality oils and position us to continue being a leader in Germany and the rest of Europe,” Franchise Cannabis CEO Clifford Starke said.
“Now that THC Global has achieved GMP certification, we’re excited to launch
a new, distinctive line of medical cannabis-derived extract products. We look forward to working with the THC Global team on many initiatives providing patient access to high-quality products,” he added.
THC is up 1.61 per cent on the market this afternoon, trading for 31.5¢ per share at 1:00 pm AEST.
